You just read:

Bausch + Lomb Announces HEALTH CANADA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%) for the Treatment of Glaucoma

News provided by

Bausch + Lomb

Jan 03, 2019, 07:30 ET